tradingkey.logo

Ekso Bionics Holdings Inc

EKSO
4.860USD
+0.040+0.83%
收盘 12/19, 16:00美东报价延迟15分钟
12.75M总市值
亏损市盈率 TTM

Ekso Bionics Holdings Inc

4.860
+0.040+0.83%

关于 Ekso Bionics Holdings Inc 公司

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.

Ekso Bionics Holdings Inc简介

公司代码EKSO
公司名称Ekso Bionics Holdings Inc
上市日期Apr 10, 2013
CEODavis (Scott G)
员工数量61
证券类型Ordinary Share
年结日Apr 10
公司地址101 Glacier Point
城市SAN RAFAEL
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94901
电话15109841761
网址https://eksobionics.com/
公司代码EKSO
上市日期Apr 10, 2013
CEODavis (Scott G)

Ekso Bionics Holdings Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Steven A. Sherman
Mr. Steven A. Sherman
Executive Chairman of the Board
Executive Chairman of the Board
449.16K
+23.08%
Ms. Mary Ann Cloyd
Ms. Mary Ann Cloyd
Independent Director
Independent Director
25.23K
+166.00%
Mr. Jason C. Jones
Mr. Jason C. Jones
Chief Operating Officer
Chief Operating Officer
19.91K
-1.34%
Mr. Jerome Wong
Mr. Jerome Wong
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
17.56K
-6.59%
Ms. Deborah Lafer Scher
Ms. Deborah Lafer Scher
Independent Director
Independent Director
15.75K
--
Dr. Charles Li, Ph.D.
Dr. Charles Li, Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott G. Davis
Mr. Scott G. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Corinna E. Lathan
Dr. Corinna E. Lathan
Independent Director
Independent Director
--
--
Mr. Stephen Kilmer
Mr. Stephen Kilmer
Investor Relations
Investor Relations
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Steven A. Sherman
Mr. Steven A. Sherman
Executive Chairman of the Board
Executive Chairman of the Board
449.16K
+23.08%
Ms. Mary Ann Cloyd
Ms. Mary Ann Cloyd
Independent Director
Independent Director
25.23K
+166.00%
Mr. Jason C. Jones
Mr. Jason C. Jones
Chief Operating Officer
Chief Operating Officer
19.91K
-1.34%
Mr. Jerome Wong
Mr. Jerome Wong
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
17.56K
-6.59%
Ms. Deborah Lafer Scher
Ms. Deborah Lafer Scher
Independent Director
Independent Director
15.75K
--
Dr. Charles Li, Ph.D.
Dr. Charles Li, Ph.D.
Independent Director
Independent Director
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
United States
1.02M
49.73%
Other EMEA
613.00K
29.80%
France
365.00K
17.74%
APAC
40.00K
1.94%
Other Americas
16.00K
0.78%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 12月4日 周四
更新时间: 12月4日 周四
持股股东
股东类型
持股股东
持股股东
占比
Davis (Scott Gerald)
2.33%
Consolidated Portfolio Review Corp
1.91%
Citadel Advisors LLC
1.14%
The Vanguard Group, Inc.
1.04%
UBS Financial Services, Inc.
0.96%
其他
92.62%
持股股东
持股股东
占比
Davis (Scott Gerald)
2.33%
Consolidated Portfolio Review Corp
1.91%
Citadel Advisors LLC
1.14%
The Vanguard Group, Inc.
1.04%
UBS Financial Services, Inc.
0.96%
其他
92.62%
股东类型
持股股东
占比
Individual Investor
6.59%
Investment Advisor
4.73%
Hedge Fund
1.57%
Investment Advisor/Hedge Fund
1.05%
Research Firm
0.33%
Family Office
0.03%
其他
85.70%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
64
261.39K
8.72%
--
2025Q3
67
261.39K
11.41%
+205.54K
2025Q2
64
55.85K
14.40%
-195.55K
2025Q1
62
251.40K
15.39%
-37.98K
2024Q4
61
283.25K
26.99%
-87.09K
2024Q3
58
370.34K
18.68%
+159.85K
2024Q2
61
145.58K
14.28%
+25.92K
2024Q1
67
120.72K
11.67%
-18.52K
2023Q4
71
95.15K
14.09%
+2.45K
2023Q3
71
92.88K
16.51%
-13.62K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Davis (Scott Gerald)
22.27K
0.85%
+7.04K
+46.23%
Mar 18, 2025
The Vanguard Group, Inc.
11.96K
0.46%
-27.61K
-69.77%
Jun 30, 2025
Li (Kecheng)
30.73K
1.18%
+15.75K
+105.11%
May 16, 2025
Lathan (Corinna)
25.61K
0.98%
+15.75K
+159.61%
May 16, 2025
Cloyd (Mary Ann)
25.23K
0.97%
+15.75K
+166.00%
May 16, 2025
Jones (Jason C)
14.90K
0.57%
+5.26K
+54.55%
Mar 18, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
May 19, 2025
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
公告日期
类型
比率
May 19, 2025
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1

常见问题

Ekso Bionics Holdings Inc的前五大股东是谁?

Ekso Bionics Holdings Inc 的前五大股东如下:
Davis (Scott Gerald)持有股份:22.27K,占总股份比例:0.85%。
The Vanguard Group, Inc.持有股份:11.96K,占总股份比例:0.46%。
Li (Kecheng)持有股份:30.73K,占总股份比例:1.18%。
Lathan (Corinna)持有股份:25.61K,占总股份比例:0.98%。
Cloyd (Mary Ann)持有股份:25.23K,占总股份比例:0.97%。

Ekso Bionics Holdings Inc的前三大股东类型是什么?

Ekso Bionics Holdings Inc 的前三大股东类型分别是:
Davis (Scott Gerald)
Consolidated Portfolio Review Corp
Citadel Advisors LLC

有多少机构持有Ekso Bionics Holdings Inc(EKSO)的股份?

截至2025Q4,共有64家机构持有Ekso Bionics Holdings Inc的股份,合计持有的股份价值约为261.39K,占公司总股份的8.72%。与2025Q3相比,机构持股有所增加,增幅为-2.70%。

哪个业务部门对Ekso Bionics Holdings Inc的收入贡献最大?

在FY2025Q2,--业务部门对Ekso Bionics Holdings Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI